Fortis Healthcare Intrinsic Value
FORTIS Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹267.76 | ₹214.21 - ₹321.31 | -70.0% | EPS: ₹17.04, Sector P/E: 12x |
| Book Value Method | asset | ₹178.51 | ₹160.66 - ₹196.36 | -80.0% | Book Value/Share: ₹121.44, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹267.76 | ₹240.98 - ₹294.54 | -70.0% | Revenue/Share: ₹126.15, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹357.02 | ₹321.32 - ₹392.72 | -60.0% | EBITDA: ₹2424.00Cr, EV/EBITDA: 6x |
| Simple DCF (5Y) | dcf | ₹357.02 | ₹285.62 - ₹428.42 | -60.0% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹267.76 | ₹240.98 - ₹294.54 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹267.76 | ₹240.98 - ₹294.54 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹446.27 | ₹401.64 - ₹490.90 | -50.0% | ROE: 14.4%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹267.76 | ₹240.98 - ₹294.54 | -70.0% | EPS: ₹17.04, BVPS: ₹121.44 |
Want to compare with current market value? Check FORTIS share price latest .
Valuation Comparison Chart
FORTIS Intrinsic Value Analysis
What is the intrinsic value of FORTIS?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Fortis Healthcare (FORTIS) is ₹267.76 (median value). With the current market price of ₹892.55, this represents a -70.0% variance from our estimated fair value.
The valuation range spans from ₹178.51 to ₹446.27, indicating ₹178.51 - ₹446.27.
Is FORTIS undervalued or overvalued?
Based on our multi-method analysis, Fortis Healthcare (FORTIS) appears to be trading above calculated value by approximately 70.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 0.50 | Industry Standard: 2.0+ | Below 1.5 | Measures short-term liquidity capacity |
| Return on Equity | 14.4% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 24.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.70x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
Related Pages for Fortis Healthcare
Additional stock information and data for FORTIS
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹1,424 Cr | ₹1,034 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹1,100 Cr | ₹656 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹822 Cr | ₹636 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹865 Cr | ₹615 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹486 Cr | ₹421 Cr | Positive Free Cash Flow | 8/10 |